Yiming Zhu

Yiming Zhu

Auto-generated profile, based on publicly available information

Yiming Zhu

Head and Neck Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Medullary thyroid carcinoma (MTC) can only be cured through the excision of all metastatic lesions, but current clinical practice fails to localize the disease in 29% to 60% of patients. Previously, we developed a fibroblast activation protein inhibitor (FAPI)-based covalent targeted radioligand (CTR) for improved detection sensitivity and accuracy. In this first-in-class clinical trial, we head-to-head compared [68Ga]Ga-CTR-FAPI PET-CT and [18F]fluorodeoxyglucose ([18F]FDG) PET-CT in 50 patients with MTC. The primary endpoint was the patient-based detection rate, with [68Ga]Ga-CTR-FAPI exhibiting higher detection than [18F]FDG (98% vs. 66%, P = 0.0002). This improved detection was attributed to increased tumor uptake (maximum standardized uptake value = 11.71 ± 9.16 vs. 2.55 ± 1.73, P < 0.0001). Diagnostic accuracy, validated on lesions with gold-standard pathology, was greater for [68Ga]Ga-CTR-FAPI compared with [18F]FDG (96.7% vs. 43.3%, P < 0.0001). Notably, the management of 32% of patients was altered following [68Ga]Ga-CTR-FAPI PET-CT, and the surgical plan was changed for 66.7% of patients. Overall, [68Ga]Ga-CTR-FAPI PET-CT provided superior detection and diagnostic accuracy compared with [18F]FDG PET-CT, enabling precision management of patients with MTC. Significance: In this first-in-class clinical trial of CTR, [68Ga]Ga-CTR-FAPI demonstrated an improved patient-based detection rate (98%), tumor uptake (maximum standardized uptake value = 11.71 ± 9.16), and pathology-validated diagnostic accuracy (96.7%) compared with the currently approved method in MTC treatment. It directly altered management in 32% of patients, enabling precision diagnosis and management of MTC. See related commentary by Witney, p. 264

24 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
YQYuquan Qian
Yuquan Qian
LTLe Tang
Le Tang
JYJiarui Yao
Jiarui Yao
YZYiming Zhu
Yiming Zhu
YZYe Zhang
Ye Zhang
LGLin Gui
Lin Gui
Purpose: Patients with recurrent or metastatic sinonasal squamous cell carcinoma (R/M SNSCC) lack standardized systemic treatment and prospective studies. We evaluated the antitumor response and safety of pembrolizumab with nab-paclitaxel and platinum in R/M SNSCC. Patients and Methods: Patients with R/M SNSCC received pembrolizumab 200 mg and nab-paclitaxel 260 mg/m2 plus cisplatin 75 mg/m2 or carboplatin at an AUC 5 on day 1 every 21 days for up to six cycles, followed by pembrolizumab maintenance until progression or unacceptable toxicity or 35 cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), and safety. IHC and high-resolution sequencing of the tumor samples were performed. Results: The ORR in 20 patients was 60.0% (95% confidence interval, 36.1%–80.9%), and two patients (2/20, 10%) achieved complete response. The disease control rate was 100%. The median follow-up was 18.1 months (range, 5.2–31.7), the median PFS was 12.2 months (95% confidence interval, 9.0 months–not estimated), and the median OS was not reached. Patients with a PD-L1 combined positive score ≥20 exhibited better ORR (80.0% vs. 28.6%, P = 0.144), median PFS (not reached vs. 7.0 months, P = 0.0137), and median OS (not reached vs. 17.8 months, P = 0.0401) compared with those with a PD-L1 combined positive score <20. Grade 3/4 treatment-related adverse events (AE) accounted for 30.0% (6/20) of AEs, and all were hematologic toxicities. Hypothyroidism was the most common immune-related AE (12/20, 60.0%). Conclusions: Pembrolizumab plus nab-paclitaxel and platinum shows promising antitumor activity and manageable safety in patients with first-line R/M SNSCC.


21 April 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
ZKZiren Kong
Ziren Kong
YLYang Liu
Yang Liu
YLYan-Song Lin
Yan-Song Lin
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
SLShaoyan Liu
Shaoyan Liu
Purpose: Medullary thyroid carcinoma (MTC) is curable only by complete resection of all malignant lesions; however, biochemical cure rates remain suboptimal because of imprecise lesion localization. We previously developed a covalent targeted radioligand fibroblast activation protein inhibitor (CTR-FAPI-30) with superior MTC detection rate and accuracy. This study evaluated whether [68Ga]Ga-CTR-FAPI-30 positron emission tomography–computed tomography (PET-CT)–guided surgery improves patient outcomes. Patients and Methods: In this prospective, open-label phase II clinical trial, 50 patients with MTC were enrolled and underwent [68Ga]Ga-CTR-FAPI-30 PET-CT–guided surgery. Patients were stratified into three predefined arms: (i) newly diagnosed MTC, R0 resection; (ii) recurrent MTC, R0 resection; and (iii) unresectable disease or distant metastasis. The primary endpoint was the biochemical cure rate at 1 month postoperatively. Secondary endpoints included event-free survival, the diagnostic accuracy of [68Ga]Ga-CTR-FAPI-30, and surgical plan modification rate. Results: The biochemical cure rates were favorable under [68Ga]Ga-CTR-FAPI-30–guided surgery, with 84.2% [95% confidence interval (CI), 60.4%–96.6%] in arm 1 (newly diagnosed, R0 resection) and 46.7% (95% CI, 21.3%–73.4%) in arm 2 (recurrent, R0 resection), both of which exceeded historical data (P = 0.007–0.049). For 231 lesions with gold-standard pathology, [68Ga]Ga-CTR-FAPI-30 demonstrated superior diagnostic accuracy (96.5% vs. 72.7%, P < 0.0001), sensitivity (98.5% vs. 81.7%, P < 0.0001), and specificity (85.3% vs. 20.6%, P < 0.0001) compared with conventional imaging. Surgical plans were modified in 46% of patients based on [68Ga]Ga-CTR-FAPI-30 PET-CT compared with investigator-determined approaches, with 91% of these modifications histopathologically justified. Conclusions: [68Ga]Ga-CTR-FAPI-30–guided surgery achieved favorable biochemical cure rates for both newly diagnosed MTC and recurrent MTC, enabling precision surgical resection through accurate lesion localization.

1 May 2025
Verified
Other
Open access
YQYuquan Qian
Yuquan Qian
LTLe Tang
Le Tang
JYJiarui Yao
Jiarui Yao
YZYiming Zhu
Yiming Zhu
YZYe Zhang
Ye Zhang
LGLin Gui
Lin Gui
Purpose:Patients with recurrent or metastatic sinonasal squamous cell carcinoma (R/M SNSCC) lack standardized systemic treatment and prospective studies. We evaluated the antitumor response and safety of pembrolizumab with nab-paclitaxel and platinum in R/M SNSCC.Patients and Methods:Patients with R/M SNSCC received pembrolizumab 200 mg and nab-paclitaxel 260 mg/m2 plus cisplatin 75 mg/m2 or carboplatin at an AUC 5 on day 1 every 21 days for up to six cycles, followed by pembrolizumab maintenance until progression or unacceptable toxicity or 35 cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), and safety. IHC and high-resolution sequencing of the tumor samples were performed.Results:The ORR in 20 patients was 60.0% (95% confidence interval, 36.1%–80.9%), and two patients (2/20, 10%) achieved complete response. The disease control rate was 100%. The median follow-up was 18.1 months (range, 5.2–31.7), the median PFS was 12.2 months (95% confidence interval, 9.0 months–not estimated), and the median OS was not reached. Patients with a PD-L1 combined positive score ≥20 exhibited better ORR (80.0% vs. 28.6%, P = 0.144), median PFS (not reached vs. 7.0 months, P = 0.0137), and median OS (not reached vs. 17.8 months, P = 0.0401) compared with those with a PD-L1 combined positive score <20. Grade 3/4 treatment-related adverse events (AE) accounted for 30.0% (6/20) of AEs, and all were hematologic toxicities. Hypothyroidism was the most common immune-related AE (12/20, 60.0%).Conclusions:Pembrolizumab plus nab-paclitaxel and platinum shows promising antitumor activity and manageable safety in patients with first-line R/M SNSCC.